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ABSTRACT 
Yttrium-90 is a radioelement which has found wide use in targeted radionuclide therapy 
because of its attractive physical and chemical properties. Radioembolisation of 
hepatocellular carcinoma with radiolabelled Lipiodol is a method of choice. We have 
synthesised a series of alkyldithiocarbamate yttrium complexes, easily extracted into Lipiodol 
due to their high lipophilicity. Among the prepared series, a new radioconjugate, which is 
stable over an extended period of time, has been prepared, and could represent a potential 
treatment procedure for hepatocellular carcinoma. 
Keywords: Dithiocarbamate; 1,10-phenanthroline; Hepatocellular carcinoma; Lipiodol; 
Radionuclide therapy; Yttrium-90 
1- Introduction 
Hepatocellular carcinoma (HCC), the most common form of primary liver cancers, is the fifth 
most common tumour worldwide, and even ranks third in terms of mortality (Ferlay et al., 
2010; Jemal et al., 2011). For the vast majority of patients not eligible to curative treatments, 
such as resection or transplantation, there is a wide range of palliative treatments which can 
be proposed, among which are chemoembolisation and radioembolisation with Lipiodol or 
microspheres (Venook, 1994; Thomas and Zhu, 2005; Liapi and Geschwind, 2010; Lencioni, 
2010; Raoul et al., 2010). Lipiodol is an oily medium which has shown to be selectively 
retained in tumour when administered intra-arterially (Chou et al., 1995). Lipiodol has been 
labelled with iodine-131 (Liebster and Kocandrle, 1964; Raoul et al., 1986), rhenium-188 
(Lepareur et al., 2008), yttrium-90 (Wang et al., 1996b; Yu et al., 2003), and radiolanthanides 
(Das et al., 2009; Subramanian et al., 2010). Yttrium-90 (pure beta-emitter, EEmax = 2.27 
MeV, t1/2 = 64 h, max tissue penetration = 12 mm) has ideal properties for targeted 
radiotherapy, and has found wide use in peptide receptor radionuclide therapy (Goffredo et 
al., 2011), radioimmunotherapy (Sharkey et al., 2010) and radioembolisation (Salem and 
Hunter, 2006). It has been suggested as a suitable isotope to label Lipiodol as it should lead to 
a significantly reduced whole-body dose compared to 131I-Lipiodol, since more than 90 % of 
this dose is due to the emitted gamma rays (respectively 0.02 rad/mCi compared to 1.9 
rad/mCi, based on estimated dosimetry) (Madsen et al., 1988). After having successfully 
developed radiolabelled Lipiodol with rhenium-188 (Lepareur et al., 2004; Lepareur et al., 
2012), we decided to develop a new labelling of Lipiodol with yttrium-90 for the treatment of 
HCC, as a complementary tool in the treatment armamentarium. A series of heteroligand 
yttrium dialkyldithiocarbamate complexes with 1,10-phenanthroline has been prepared, and 
their suitability to label Lipiodol has been investigated. 
2- Experimental 
2.1. Materials and Methods 
Yttrium-90 was obtained from IBA as yttrium chloride in HCl 0.04 M (Ytracis, CIS bio 
International/IBA, Gif-sur-Yvette, France). Lipiodol was obtained from Guerbet (Villepinte, 
France). 1,10-Phenanthroline was purchased from Acros (Illkirch, France). Sodium 
diethyldithiocarbamate was purchased from Aldrich (Saint Quentin Fallavier, France). Other 
dithiocarbamates were synthesised according to the literature from the corresponding 
secondary amines and carbon disulfide. Briefly, in a 100 mL round-bottom flask, under 
nitrogen, 14 mmol of N-methylalkylamine were diluted in 30 mL diethyl ether. The round-
bottom flask was cooled down to -15°C in an ice/salt bath. 532 mg (13.3 mmol) of sodium 
hydroxide in methanol were added under stirring. 1.1g (14.6 mmol) of carbon disulfide were 
slowly added under stirring. The mixture was stirred for 30 minutes in the ice/salt bath, then 
at room temperature for 90 minutes. The obtained precipitate was filtered then dried under 
vacuum to give a white powder. 
Non-radioactive compounds were characterized by 1H and 13C NMR recorded with a 
BRUKER ARX 400 (Billerica MA, USA) at 400.13 and 100.62 MHz, respectively, in CDCl3,
calibrated internally to the residual solvent. ES mass analysis was done on a Shimadzu LCMS 
2020 (Kyoto, Japan). Activity measurements were done in a CRC-127R well-counter 
(Capintec Inc., Ramsey NJ, USA). TLC analyses were done on ITLC-SG plates (Pall Life 
Sciences, Ann Arbor MI, USA) with methanol as mobile phase. The plates were analysed 
with a Perkin Elmer Cyclone Storage Phosphor Imager, using the Packard Optiquant v04.00 
software. 
2.2. Preparation of [
89
Y(DEDC)3(Phen)] (C1)
MW = 713 
In a 20 mL round-bottom flask, under nitrogen, 180 mg (1 mmol) of 1,10-phenanthroline, 
dissolved in 2 mL methanol, and 675 mg (3 mmol) of sodium N,N-diethyldithiocarbamate 
trihydrate, dissolved in 2 mL methanol, are placed. 200 mg (1 mmol) of yttrium chloride were 
dissolved in 2 mL methanol and were added dropwise to the ligands. The complex 
precipitated. The mixture was stirred for 20 minutes at room temperature then filtered, 
washed with methanol, and dried under vacuum to give C1 as white crystals (619 mg, 87 %). 
1H NMR (CDCl3): 9.99 (dd, J = 4.9, 1.5 Hz, 2H, H-Phen), 8.37 (dd, J = 8.1, 1.6 Hz, 2H, H-
Phen), 7.85 (s, 2H, H4), 7.72 (dd, J = 8.1, 4.9 Hz, 2H, H-Phen), 3.83 (q, J = 7.1 Hz, 12H, 
NCH2), 1.12 (t, J = 7.1 Hz, 18H, CH3).
13C NMR (CDCl3): 205.8 (CS2), 151.8 (CH-Phen), 
144,9 (C-Phen), 137.9 (CH-Phen), 129.4 (C-Phen), 126.8 (CH-Phen), 123.5 (CH-Phen), 46.1 
(NCH2), 12.4 (CH3). m/z = 713.40. Rf (MeOH) = 0.76. 
2.3. Preparation of [
90
Y(dtc)3(Phen)] and Lipiodol radiolabelling 
100 µL of 90YCl3 in acetate buffer (pH = 4.75) were added to a solution of 100 µL of sodium 
dithiocarbamate 15.10-2 M in ethanol and 100 µL of phenanthroline 5.10-2 M in ethanol. 
Several parameters such as concentration of ligands, volume and pH of the reaction mixture, 
incubation time, and temperature were varied extensively to arrive at the optimised protocol. 
For the preparation of 90Y-Lipiodol, [90Y(dtc)3(Phen)] complex prepared under optimised 
reaction conditions was extracted in 2 mL Lipiodol. After vigorous shaking for 2 minutes to 
ensure homogeneous dispersion of the complex in Lipiodol, the phases were separated by 
centrifugation. Chemical identity of the radiotracer was assessed for [90Y(DEDC)3(Phen)] by 
comparing its TLC profile in MeOH with that of the fully characterised analogous non-
radioactive complex C1. Other dithiocarbamates tracers were assumed to have similar 
structures. 
2.4. Determination of complexation yield of [
90
Y(dtc)3(Phen)] 
The complexation yield of the [90Y(dtc)3(Phen)] radiotracer prepared was determined by 
solvent extraction technique. 300 µL of chloroform were added. The mixture was vigorously 
shaken, then centrifuged (3840 rpm, 15 min) to separate the phases. The two phases were 
carefully collected and counted in a well-counter. The complexation yield was determined as 
the organic layer activity on the total (aqueous + organic) activity. 
2.5. Determination of labelling yield of Lipiodol 
The labelling yield of Lipiodol was determined by an analogue technique. 900 µL of saline 
and 2 mL of Lipiodol were added. The mixture was vigorously shaken, and then centrifuged 
(3840 rpm, 15 min) to separate the phases. The two phases were carefully collected and 
counted in a well-counter. The complexation yield was determined as the Lipiodol layer 
activity on the total (aqueous + Lipiodol) activity. 
2.6. In vitro stability of 
90
Y-Lipiodol
To check the in vitro stability of 90Y-labelled Lipiodol, 2 mL of saline was added to the 
preparation and mixed vigorously. The mixture was allowed to settle at room temperature. 
100 µL of aliquots were withdrawn from both layers at different time intervals post-
preparation and the associated activity was counted. The stability of the radiolabelled 
preparation at various time points was determined by calculating the percentage of activity 
associated with the lipid phase from these data. 
3- Results and Discussion 
When injected through the hepatic artery, Lipiodol, an iodinated mixture of esterified 
poppyseed oil, is selectively trapped in tumour cells (HCC and some hepatic metastases) 
(Nakakuma et al., 1985). Besides, Lipiodol displays a prolonged retention within the tumour, 
while it is more quickly cleared from the healthy liver (Chou et al, 1995; Kan, 1996). It has 
thus been used for the detection of HCC and as a vector for chemotherapeutic drugs 
(Bhattacharya and Dusheiko, 1995; Dalla Palma ,1998).  
When radiolabelled with iodine-131, Lipiodol has shown a high tumour-to-liver ratio, with 
some activity in the lungs (depending on arterioveinous shunts) and no activity in the thyroid, 
thus excluding iodine-131 release (Madsen et al., 1988; Raoul et al., 1988; Yoo et al., 1994). 
Covalently labelled Lipiodol with rhenium-188 and yttrium-90 demonstrated a biodistribution 
similar to 131I-Lipiodol (Wang et al., 1996a; Wang, et al., 1996b). This approach was however 
disappointing, and it was demonstrated that solubilisation of a labelled lipophilic chelate into 
Lipiodol was a better approach (Jackson et al., 2000). To efficiently interact with Lipiodol, 
the radiocomplex has to be conveniently lipophilic. Other important criteria when choosing 
which ligands to use are ease of labelling and, as much as possible, known toxicity and 
compatibility for in vivo use (to facilitate acceptance for human use). One type of ligands that 
fits these criteria is dialkyldithiocarbamates (dtc). Lipophilicity can easily be modified by 
modulating the length of the alkyl chain. Several radiopharmaceutical complexes have been 
described with dithiocarbamates, with indium-113m (Abram et al., 1985), copper-62 
(Matsumoto et al., 1990), bismuth-212 (Parks et al., 1992), technetium-99m (Pasqualini et al., 
1994), and rhenium-188 (Boschi et al., 2004). Moreover, rare earth complexes with 
dithiocarbamates have been the subject of an abundant literature and their structures have 
been extensively discussed (Nief, 1998; Cotton, 2004; Hitchcock et al., 2004; Regulacio et al., 
2005). Reaction of yttrium and lanthanides with dithiocarbamates can results in ternary 
neutral complexes or quaternary anionic complexes. In the first case, lanthanides favouring 
octa-coordinated structure, the coordination sphere of the metal is usually completed with 
solvents molecules, such as [Ln(Me2dtc)3(DMSO)2] (Ln = La, Pr, Nd, Sm-Tb) (Su et al., 
1995) or [Ln(Me2dtc)3(THF)2] (Ln = Ce, Nd, Tb) (Hitchcock et al., 2004), or else with the 
addition of a neutral S-donor ligand such as 2,2’-bipyridyl or 1,10-phenanthroline (Su et al., 
1996; Regulacio et al., 2008). With this additional ligand, there is an easy electron 
delocalisation among the large conjugate system which, as well as the rigid plane, enables a 
stable crystal packing, thus enhances the stability of the complex (Su et al., 1999). Mixed 
dithiocarbamate-phenanthroline yttrium and lanthanide complexes are easily synthesised in 
soft conditions, readily crystallize and are air-stable. Some may even be prepared in aqueous 
media (Ivanov et al., 2002). This can be advantageous for the preparation of radiotracers. On 
the contrary, without the neutral bidentate ligand, complexes of the [Ln(dtc)3] type are 
unstable and hydrolyze rapidly, necessitating inert atmosphere and strongly anhydrous 
conditions (Brown and Holah, 1968). Therefore, 1,10-phenanthroline was chosen to complete 
the coordination sphere of the yttrium complexes. 
Important factors for the optimal radiolabelling of the 90Y-radiotracer are the solvent, volume, 
temperature, incubation time and concentration of the components. Their effects were thus 
studied. Ligands with different alkyl chain lengths were also investigated. It appeared that the 
lower was the volume, the higher was the reaction yield. EtOH was chosen to dissolve the 
ligands, as it is the most compatible solvent for human injection. Concentrations of the 
ligands were varied from 10-3 to 10-1 M – with a 3:1 ratio for dtc:Phen – to ascertain the 
optimum ligand concentration required for maximum complexation. It was found that 15.10-2
M for dithiocarbamate and 5.10-2 M for 1,10-phenanthroline gave the best results. 
Concerning the pH of the reaction medium, a slightly acidic pH was found to give the best 
results (Figure 2). In neutral to basic pH, yttrium chloride quickly hydrolyses to insoluble 
Y(OH)3, thus preventing the reaction to proceed correctly. When the reaction medium was too 
acidic, the reaction did not proceed as well, because the dithiocarbamate is under the 
dithiocarbamic acid form (i.e. pKa of the diethyldithiocarbamic acid/diethyldithiocarbamate 
couple is 3.37 (Aspila et al., 1970)) which cannot bind to the metal. The reaction thus 
proceeded in ammonium acetate buffer (pH = 4.75). 
Temperature and reaction time were also investigated, with the DEDC ligand, and it was 
demonstrated that room temperature gave the best results (Figure 3). It was not necessary to 
let the reaction proceed for a long time, since after 5 minutes, the yield did not improve 
(Figure 4). This is advantageous in radiopharmaceutical synthesis, even if, with the 64-h half-
life of yttrium-90, this is not crucial. For comparison, Yu et al. (Yu et al., 2003) have chelated 
8-hydroxyquinoline (oxine) with yttrium-90 to label Lipiodol. The 90Y-oxine complex is 
prepared in 30 min at 50°C. As well, the covalent binding of Lipiodol and yttrium-90 via an 
N,N,N’,N’-tetrakis (2-benzymidazolylmethyl)-1,2-ethanediamine (EDTB) chelate (Wang et 
al., 1996b) necessitated a 4-hour preparation. 
Several dithiocarbamates, with different chain lengths, were investigated to find the optimal 
complex to label Lipiodol. The optimised procedure (pH = 4.75, 5 min at room temperature) 
was used. There were no significant differences between two carbons (DEDC, L1) and twelve 
carbons, L3. All complexes were obtained in high yield. On the other hand, with the sixteen 
carbons alkyl chain L4 ligand, labelling yield decreased to 62.95 ± 8.86 % (Figure 5), most 
likely due to steric hindrance. Indeed, stability of lanthanide dithiocarbamate complexes 
highly relies upon steric effects of the dithiocarbamate substituent (Siddall, III and Stewart, 
1970). Increasing the reaction time with L4 did not change the outcome. 
This trend is confirmed when labelling Lipiodol with these complexes (Figure 6). Using the 
long-chain L4 dithiocarbamate ligand, the labelling yield decreased to 64 %. This low yield 
was not due to poor extraction of the highly lipophilic complex, but because of the low 
formation of this compound, as most of the activity was free 90Y. Labelling yield was also 
somewhat lower with [90Y(L1)3Phen] compared to [
90Y(L3)3Phen], due to the lower 
lipophilicity of the complex. TLC profiles, on ITLC-SG plates in methanol, showed only one 
spot, thus indicating only one species in the organic phase. Comparison of TLC profiles for 
[Y(DEDC)3(Phen)], both prepared at macromolecular scale (characterised by NMR and 
electrospray mass analysis) and at tracer level, confirmed the chemical identity of the 
radiotracer (Rf = 0.76). 
Labelling Lipiodol with [90Y(dtc)3Phen] is easy and consists more precisely in an extraction 
of the yttrium complex into the Lipiodol phase (Mu et al., 2007). Selective extraction was 
attained with 5-minute shaking at room temperature, without the need for intermediate 
organic solvent extraction and subsequent evaporation, as was the case for the oxine 
complexes, which required an extraction into dichloromethane prior to solubilisation in 
Lipiodol (Yu et al., 2003; Das et al., 2009; Subramanian et al., 2010). 
In vitro stability has been checked in saline, over a period of 8 days (Figure 7). Here, 
[90Y(L1)3Phen] appeared to be more stable than [
90Y(L3)3Phen]. Indeed, the latter complex 
was more easily released from Lipiodol, this release increasing with time, while 80 % of the 
activity remains in Lipiodol with [90Y(L1)3Phen]. 
4- Conclusions 
A new method for the 90Y-labelling of Lipiodol has been demonstrated. Based on labelling 
yields and in vitro stability, [90Y(DEDC)3(Phen)] seems to be the best candidate. Animal 
experiments are underway to check the biodistribution profile and in vivo stability of the 
radioconjugate. Lipiodol labelling with stronger activities (therapeutic doses) of yttrium-90 is 
also envisaged, to ascertain potential autoradiolysis. For this, automation of the synthesis is 
planned. 
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Figure 1: Structure of the mixed ligand yttrium complexes [Y(dtc)3(Phen)] 
Figure 2: Influence of the pH on the radiosynthesis of [90Y(L1)3Phen]
Figure 3: Influence of the temperature on the radiosynthesis of [90Y(L1)3Phen] 
Figure 4: Influence of the reaction time on the radiosynthesis of [90Y(L1)3Phen] 
Figure 5: Influence of the alkyl chain length on the radiosynthesis (5 min, RT) 
Figure 6: Influence of the alkyl chain length on the radiolabelling of Lipiodol (5 min, RT) 
Figure 7: In vitro stability of the radiotracers [90Y(L1)3Phen] and [
90Y(L3)3Phen]
Table 1: The different ligands studied for the preparation of yttrium complexes
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